Skip to main content
Caplight Logo









TCRCure Biopharma

TCRCure Biopharma

Private
Beijing, BeijingHealthcare & Life Scienceshttps://www.tcrcure.com

Last Round

Series B

Feb 16, 2022

Total Funding Raised

$47.3M

Company Overview

TCRCure is a biotechnology company specializing in the development of cancer immunotherapies through advanced techniques such as high throughput antigen-specific TCR cloning, large-scale virus production, T cell genetic engineering, and immune cell manufacturing.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Application

Keywords

TCR-T cell therapyCAR-T cell therapycell therapysolid tumor therapycancer immunotherapyliving drugsT-cell engineeringautologous cell therapyclinical-stage biopharmaTCR discoveryAI drug discoverygene therapyin-house manufacturingdrug discovery platform

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

TCRCure Biopharma Comparables

Compare TCRCure Biopharma with similar companies based on industry and business-model similarity.

TCRCure Biopharma comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Lion TCR
89%
T-Knife
86%
BioSyngen
85%

TCRCure Biopharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BFeb 16, 2022
Series BDec 28, 2018
Series AApr 1, 2018

Key People

Founding team and executive leadership

Si Li

Chief Technology Officer

Executive Team

TCRCure Biopharma Investors

Notable investors and investment history

TCRCure Biopharma investors
InvestorRounds
Emerging Technology PartnersSeries B
CCB Financial Assets InvestmentSeries B
德同资本Series B
Share CapitalSeries B
Founder Hesheng Investment Co., Ltd.Series B

TCRCure Biopharma Filings

Explore SEC and related filing metadata, where available.

TCRCure Biopharma filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about TCRCure Biopharma's valuation, stock price, and market status.

Is TCRCure Biopharma a public or private company?

TCRCure Biopharma is a private company.

What is the current stock price of TCRCure Biopharma?

TCRCure Biopharma is a private company with no public stock price. No recent secondary market data is available.

How much is TCRCure Biopharma worth (valuation)?

Valuation information for TCRCure Biopharma is not publicly available.

Can I buy TCRCure Biopharma stock?

TCRCure Biopharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was TCRCure Biopharma's last funding round?

TCRCure Biopharma's most recent funding round was Series B on February 16, 2022.

Who are the main investors in TCRCure Biopharma?

Key investors in TCRCure Biopharma include CCB Financial Assets Investment.

Will TCRCure Biopharma IPO soon?

No public IPO plans have been announced for TCRCure Biopharma.

How can I track TCRCure Biopharma secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor TCRCure Biopharma's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersBeijing, Beijing
Employee Range18
Year Founded2016
Last FundingFeb 16, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?